CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
REVENUES:
Grant income	$ 11	$ 1,487
Royalties from product sales and license fees	110	200
Subscription and advertisement revenues	264	343
Sale of research products	5	43
Total revenues	390	2,073
Cost of sales	(57)	(225)
Gross profit	333	1,848
OPERATING EXPENSES:
Research and development	6,494	13,734
General and administrative	5,101	11,872
Total operating expenses	11,595	25,606
Loss from operations	(11,262)	(23,758)
OTHER INCOME/(EXPENSES):
Interest expense, net	(306)	(132)
BioTime's share of losses in equity method investment in Ascendance Biotechnology, Inc.	0	(235)
Gain on deconsolidation of OncoCyte	71,697	0
Loss on equity method investment in Asterias at fair value	(26,097)	0
Gain on equity method investment in OncoCyte at fair value	16,142	0
Other income, net	727	128
Total other income/(expense), net	62,163	(239)
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	50,901	(23,997)
Deferred income tax provision	(3,877)	0
NET INCOME (LOSS)	47,024	(23,997)
Net loss attributable to non-controlling interest	2,264	6,885
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	$ 49,288	$ (17,112)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ 0.46	$ (0.19)
DILUTED (in dollars per share)	$ 0.46	$ (0.19)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	106,712	90,421
DILUTED (in shares)	107,384	90,421